AI-based cfDNA fragmentome liquid biopsy can detect early liver fibrosis, cirrhosis, and indicate broader chronic disease signals.
Key Details
- 1Johns Hopkins team applied AI and genome-wide cfDNA fragmentation analysis to diagnose early liver fibrosis and cirrhosis.
- 2Study analyzed samples from 1,576 people with liver disease and comorbidities using whole-genome sequencing.
- 3AI algorithms identified disease-specific fragmentation patterns, enabling high sensitivity detection of early liver disease.
- 4Current clinical tests often miss early fibrosis and only detect cirrhosis around 50% of the time.
- 5Prototype assay also signaled risk for other chronic diseases, such as cardiovascular and inflammatory conditions.
- 6Technology builds upon earlier cancer fragmentome studies, focusing now on non-cancer chronic conditions.
Why It Matters
Early detection of liver fibrosis is critical because it is reversible at early stages, potentially preventing progression to cirrhosis and cancer. This AI-enabled cfDNA approach could expand the role of noninvasive liquid biopsy in radiological diagnostics and broader chronic disease management.
Source
EurekAlert
Related News
•EurekAlert
AI-Powered OCT Enables Rapid 'Optical Biopsy' for Early Endometrial Cancer Detection
A team at Washington University has developed a catheter-based 3D OCT system with AI to quickly and noninvasively detect early endometrial cancers.
•EurekAlert
AI Clinical Reasoning in Diagnostics and Digital Fatigue in Healthcare
Recent JMIR features explore large language models in clinical diagnostics and digital fatigue among healthcare professionals.
•EurekAlert
KAIST, MIT, Microsoft Develop Efficient AI Image Upsampling for Robotics
KAIST, MIT, and Microsoft have created 'Upsample Anything,' a training-free AI method to restore high-resolution visual data from compressed images with up to 16x improved GPU memory efficiency.